Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in Alzheimer's Disease Psychosis
NCT02035553Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in Alzheimer's disease (AD), sponsored by Acadia Pharmaceuticals. Started Nov 2013; status: completed.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02035553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035553.